Search Results for: THERAPEUTIC FOCUS Targeted Payload Therapies

Articles

November 12, 2018

GENETIC MODIFICATION THERAPIES – Clinical Applications & Technology Platforms November 12, 2018

Laurie L. Sullivan and John Bergin, MS, MBA, say the growing interest on the part of large pharma or biotech companies is driving clinical development of genetic modification therapy candidates, and the rich late-stage pipeline for genetic modification therapy candidates is a driving force of growth.

November 7, 2016

PLATFORM TECHNOLOGY – ​​The 3DNA® Platform for Targeted Drug Delivery November 7, 2016

Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.

October 3, 2016

SPECIAL FEATURE – Platform Technologies: Not Just for Big Pharma October 3, 2016

Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.

November 19, 2014

NANOTECHNOLOGY MARKET – Nanotechnology Markets in Healthcare & Medicine November 19, 2014

Kevin James, Jackson Highsmith, and Paul Evers report the global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate of 22%. The biggest increase will come in the area of drug delivery systems.

April 1, 2014

ANTIBODY DRUG CONJUGATES – ADC Development Using SMARTag(TM) Technology April 1, 2014

Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.

November 29, 2012

12/5/2012 November 29, 2012

Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group,...
August 26, 2012

8/29/2012 August 26, 2012

Synergy Pharmaceuticals Acquires BMS Drug Synergy Pharmaceuticals Inc. recently announced it has signed an Asset Purchase Agreement with Bristol-Myers Squibb...
May 20, 2012

5/23/2012 May 20, 2012

Agilent to Acquire Cancer Diagnostic Company for $2.2 Billion Agilent Technologies Inc. and EQT, the Sweden-based private equity group, recently...
March 7, 2012

3/13/2012 March 7, 2012

Aegerion Pharmaceuticals Submits US & EU Marketing Applications Aegerion Pharmaceuticals, Inc. recently announced it has submitted an NDA to the...